Wolwo Pharma(SZ:300357)2024-10-24 10:07Financial Performance - In the first nine months of 2024, the company achieved operating revenue of ¥730,238,304.07, representing an 8.38% increase compared to the same period last year [1] - The sales revenue of the "Dust Mite Drops" product was ¥700,513,594.48, with a year-on-year growth of 7.22% [1] - The sales revenue of the "Artemisia Pollen Sublingual Drops" reached ¥20,570,536.02, marking an impressive growth of 87.53% year-on-year [1] - The sales revenue from the skin prick diagnostic kit was ¥5,690,962.31 [1] - The net profit attributable to shareholders for the first nine months of 2024 was ¥272,253,993.52, reflecting a slight increase of 0.78% year-on-year [2] Dividend Distribution - The board of directors proposed a cash dividend of ¥1.00 (before tax) per 10 shares for the year 2024 [2] Research and Development - The company is currently in the process of applying for market approval for three new allergen testing products: "Sycamore Pollen Prick Solution," "German Cockroach Prick Solution," and "Cat Dander Prick Solution" [2] - The "House Dust Mite Membrane Agent" clinical trial application has been formally accepted by the National Medical Products Administration [2][4] - The R&D pipeline includes ongoing clinical trials for several other allergen products and a diagnostic patch for IV-type allergic reactions [4] Sales and Market Strategy - The sales team has been strengthened with the recruitment of young sales managers, aiming to enhance regional responsibilities and effectiveness [3] - The sales revenue of prick testing products has increased significantly due to the approval of three new allergen testing varieties [3][4] Future Outlook - The company plans to improve its management structure and operational efficiency to achieve high-quality development [5] - There is a commitment to align product development with future economic trends and human needs, ensuring long-term growth potential [5]